

[Sulfadoxine + pyrimethamine](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines > Medicines for curative treatment](#)

ATC codes: [P01BD51](#)

EMLc

Indication

Malaria due to Plasmodium vivax ICD11 code: [1F81](#)

INN

Sulfadoxine + pyrimethamine

Medicine type

Chemical agent

List type

Core

Additional notes

Only in combination with artesunate 50 mg

Formulations

Oral > Solid: 500 mg + 25 mg tablet

EML status history

First added in 1979 ([TRS 641](#))

Changed in 1987 ([TRS 770](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Removed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Sulfadoxine + pyrimethamine](#)

DrugBank

[Sulfadoxine](#),

[Pyrimethamine](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of sulfadoxine + pyrimethamine tablets from the EML and EMLc for the curative treatment of malaria, given the recommendation to add co-packaged artesunate and sulfadoxine + pyrimethamine to the EML and EMLc for this indication.